Thousands of patients benefit from the new nivolumab cancer JAB with more than 12 diseases, and the NHS is the first in Europe to offer new injections.
Nivolumab, an injectable immunotherapy, means that patients can receive treatment for 2 weeks or monthly in 5 minutes, rather than 1 hour, via IV intravenous drip.
The rollout allows patients and NHS teams to save on treatment time for a year a year, allowing patients to unlock staff capabilities and provide more appointments and treatment while reducing their time at the hospital.
Increased benefits of nivolumabu jab
Nivolumab JAB can be used to treat 15 cancer types, including skin cancer, bladder and esophagus, and is estimated to benefit approximately 1,200 UK patients per month.
This is a follow-up to approvals from the UK’s drug regulatory authority, MHRA.
Professor Peter Johnson, National Clinical Director of Cancer for NHS England, said: “This treatment is used for 15 different diseases, allowing thousands of valuable clinicians to free up time each year, allowing teams to treat more patients and support hospital capabilities.
“This is just the latest development in the NHS’ ongoing commitment to providing patients with the latest cancer treatments and treatment options that truly change their lives.”
In clinical trials, the patient was very pleased with the subcutaneous injection. This was prioritized over the drug IV form that took 3-5 minutes to dossier and took 30-60 minutes every 2 or 4 weeks depending on the type of cancer.
Approximately two out of five patients receiving IV nivolumab, one of the most widely used cancer treatments, should be eligible for the new JAB.
NHS staff managing JAB save approximately 1,000 hours of treatment time for patients and clinicians each month. This is equivalent to more than one year of time per year.
We will deploy clinical healthcare vaccines
The most eligible new patients are also expected to begin using nivolumab in injectable form.
NHS Cancer Services will prepare to treat first patients with new treatments, where the product supply has been received in the UK next month, helping to unlock valuable resources for nursing and pharmacy teams, and will support the capacity demand for cancer day units where the drug is currently being administered.
This is the latest in a series of NHS cancer treatment innovations introduced to save time and improve access to patients, including the rollout of new injections for breast cancer, multiple sclerosis and blood disorders.
“This is a big win for the NHS, equivalent to a year’s worth of treatment time, and can be used to provide other care and can be built on the great advances that have been made over the past six months,” commented Elizabeth O’Mahony, chief financial officer of NHS England.
The rollout forms part of NHS England’s three-pillar approach, providing the best value from the medicines. It combines cutting-edge innovations such as potential sickle cell treatments and life-changing cystic fibrosis drugs. Smarter use of biosimilars and generics that provide hundreds of millions of savings per year. And new treatments like these will unlock clinical capabilities and improve the patient’s experience.
Source link
